logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Starry Education (06698.HK) repurchased 15,500 shares for HKD 12.7 thousand on July 14th.

date
15/07/2026
According to the information from the Capital and Economics APP, Star China (06698.HK) announced on July 14, 2026, that the company will spend 12,700 Hong Kong dollars to repurchase 15,500 shares, with a repurchase price of 0.79-0.83 Hong Kong dollars per share.
Latest
2 m ago
Bank of America calls out to the market: Consumer "wallets" remain stable, concerns over price pressures exaggerated, full-year net interest income targets higher limit.
3 m ago
Only took three days! SK Hynix (SKHY.US) ADR's premium over South Korean domestic stocks has widened to 51%, with top institutions collectively bullish.
4 m ago
OpenAI responds to Apple's commercial secret lawsuit: Lawsuit has no factual basis.
4 m ago
Institution: In July, there was a worsening mismatch between supply and demand in the TV panel market, leading to overall price weakening.
4 m ago
Coronbot Bio (06990.HK): The core product TROP2ADC sacituzumab govitecan (sac-TMT) combined with pembrolizumab achieved the primary endpoint in a Phase 3 clinical study for first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with PD-L1 negativity.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.